Table 1 Demographic and clinical characteristics of 141 colorectal cancer patients
| Variables |
LS group (N = 47) |
SCRC group (N = 94) | χ2 value | p value |
|---|---|---|---|---|
| Age (years) | 0.070 | 0.792 | ||
| < 50 | 35(74.5%) | 68(72.3%) | ||
| ≥50 | 12(2.5.5%) | 26(27.7) | ||
| Gender | 0.058 | 0.810 | ||
| Male | 26(55.3%) | 54(57.4%) | ||
| Female | 21(44.7%) | 40(42.6%) | ||
| CEA (ng/ml) | 0.104 | 0.747 | ||
| ≥5.2 | 7(14.9%) | 16(17.0%) | ||
| < 5.2 | 40(85.1%) | 78(83.0%) | ||
| Location | 3.177 | 0.365 | ||
| Right colon | 18(38.3%) | 40(42.6%) | ||
| Left colon | 20(42.6%) | 41(43.6%) | ||
| Rectal | 5(10.6%) | 11(11.7%) | ||
| Multiple | 4(8.5%) | 2(2.1%) | ||
| Tumor size a (cm) | 5.17±2.61 | 5.21±2.79 | 0.106 | 0.754 |
| Pathological classification | 0.474 | 0.789 | ||
| Adenocarcinoma | 34(72.3%) | 71(75.5%) | ||
| Partial mucinous | 5(10.7%) | 11(11.7%) | ||
| Mucinous adenocarcinoma | 8(17.0%) | 12(12.8%) | ||
| Differentiation grade | 0.259 | 0.878 | ||
| Well | 1(2.1%) | 1(1.1%) | ||
| Moderately | 28(59.6%) | 56(59.5%) | ||
| Poorly | 18(38.3%) | 37(39.4%) | ||
| Cancerous node | 0.534 | 0.465 | ||
| Occurrence | 2(4.3%) | 7(7.4%) | ||
| Absence | 45(95.7%) | 87(92.6%) | ||
| Vascular invasion | 0.534 | 0.461 | ||
| Occurrence | 8(17.0%) | 21(22.3%) | ||
| Absence | 39(83.0%) | 73(77.7%) | ||
| Perineural invasion | 0.252 | 0.616 | ||
| Occurrence | 6(12.8%) | 15(16.0%) | ||
| Absence | 41(87.2%) | 79(84.0%) | ||
| T stage | 0.130 | 0.937 | ||
| T1 | 7(14.9%) | 12(12.8%) | ||
| T2 | 8(17.0%) | 17(18.1%) | ||
| T3 | 32(68.1%) | 65(69.1%) | ||
| N stage | 1.840 | 0.399 | ||
| N0 | 34(72.3%) | 57(60.6%) | ||
| N1 | 9(19.1%) | 23(24.5%) | ||
| N2 | 4(8.6%) | 14(14.9%) | ||
| Metastasis | 0.265 | 0.607 | ||
| Occurrence | 2(4.3%) | 6(6.4%) | ||
| Absence | 45(95.7%) | 88(93.6%) | ||
| TNM stage | 1.200 | 0.753 | ||
| I | 13(27.7%) | 27(28.7%) | ||
| II | 17(36.2%) | 30(31.9%) | ||
| III | 15(31.8%) | 31(33.0%) | ||
| IV | 2(4.3%) | 6(6.4%) | ||
| KRAS mutant | 21(44.6%) | 49 (52.1%) | 0.695 | 0.404 |
| NRAS mutant | 2(4.3%) | 3 (3.2%) | 0.104 | 0.747 |
| Adjuvant chemotherapy | 1.420 | 0.233 | ||
| Received | 26(55.3%) | 42(44.7%) |
